<?xml version='1.0' encoding='utf-8'?>
<document id="28806472"><sentence text="Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers."><entity charOffset="11-25" id="DDI-PubMed.28806472.s1.e0" text="clarithromycin" /><entity charOffset="53-63" id="DDI-PubMed.28806472.s1.e1" text="evogliptin" /><pair ddi="false" e1="DDI-PubMed.28806472.s1.e0" e2="DDI-PubMed.28806472.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28806472.s1.e0" e2="DDI-PubMed.28806472.s1.e1" /></sentence><sentence text="Evogliptin (DA-1229), a novel dipeptidyl peptidase (DPP)-4 inhibitor with high potency and selectivity, was approved in Korea for the treatment of type 2 diabetes"><entity charOffset="0-10" id="DDI-PubMed.28806472.s2.e0" text="Evogliptin" /></sentence><sentence text=" Preclinical studies suggest that it is metabolized by cytochrome (CYP) P450 isozymes" /><sentence text=" Based on these findings, a clinical study was designed to investigate the pharmacokinetic (PK) interaction of evogliptin with a CYP inhibitor, clarithromycin"><entity charOffset="111-121" id="DDI-PubMed.28806472.s4.e0" text="evogliptin" /><entity charOffset="144-158" id="DDI-PubMed.28806472.s4.e1" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.28806472.s4.e0" e2="DDI-PubMed.28806472.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28806472.s4.e0" e2="DDI-PubMed.28806472.s4.e1" /></sentence><sentence text="" /><sentence text="An open-label, two-phase, crossover study was conducted with 12 healthy subjects" /><sentence text=" On day 1, a single dose of evogliptin 5 mg was administered alone to assess the reference PK profile of evogliptin"><entity charOffset="28-38" id="DDI-PubMed.28806472.s7.e0" text="evogliptin" /><entity charOffset="105-115" id="DDI-PubMed.28806472.s7.e1" text="evogliptin" /><pair ddi="false" e1="DDI-PubMed.28806472.s7.e0" e2="DDI-PubMed.28806472.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28806472.s7.e0" e2="DDI-PubMed.28806472.s7.e1" /></sentence><sentence text=" On day 10, after a 2-day pretreatment with clarithromycin, evogliptin 5 mg was administered again to evaluate the effect of CYP inhibition on the PK profile of evogliptin"><entity charOffset="44-58" id="DDI-PubMed.28806472.s8.e0" text="clarithromycin" /><entity charOffset="60-70" id="DDI-PubMed.28806472.s8.e1" text="evogliptin" /><entity charOffset="161-171" id="DDI-PubMed.28806472.s8.e2" text="evogliptin" /><pair ddi="false" e1="DDI-PubMed.28806472.s8.e0" e2="DDI-PubMed.28806472.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28806472.s8.e0" e2="DDI-PubMed.28806472.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28806472.s8.e0" e2="DDI-PubMed.28806472.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28806472.s8.e1" e2="DDI-PubMed.28806472.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28806472.s8.e1" e2="DDI-PubMed.28806472.s8.e2" /></sentence><sentence text=" Administration of clarithromycin continued until day 14"><entity charOffset="19-33" id="DDI-PubMed.28806472.s9.e0" text="clarithromycin" /></sentence><sentence text=" Blood sampling in the reference and test phases was performed until 96 and 168 hours after dosing, respectively for PK assays" /><sentence text="" /><sentence text="Eleven of the 12 subjects completed the study, and their data were analysed" /><sentence text=" In the presence of clarithromycin, exposure to evogliptin increased without any serious adverse events and the geometric mean peak plasma concentration (Cmax ) and area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-∞ ) of evogliptin increased by 116"><entity charOffset="20-34" id="DDI-PubMed.28806472.s13.e0" text="clarithromycin" /><entity charOffset="48-58" id="DDI-PubMed.28806472.s13.e1" text="evogliptin" /><entity charOffset="255-265" id="DDI-PubMed.28806472.s13.e2" text="evogliptin" /><pair ddi="false" e1="DDI-PubMed.28806472.s13.e0" e2="DDI-PubMed.28806472.s13.e0" /><pair ddi="false" e1="DDI-PubMed.28806472.s13.e0" e2="DDI-PubMed.28806472.s13.e1" /><pair ddi="true" e1="DDI-PubMed.28806472.s13.e0" e2="DDI-PubMed.28806472.s13.e2" /><pair ddi="false" e1="DDI-PubMed.28806472.s13.e1" e2="DDI-PubMed.28806472.s13.e1" /><pair ddi="true" e1="DDI-PubMed.28806472.s13.e1" e2="DDI-PubMed.28806472.s13.e2" /></sentence><sentence text="5% and 89" /><sentence text="6%, respectively" /><sentence text="" /><sentence text="Administration of clarithromycin significantly increased exposure to evogliptin in healthy subjects"><entity charOffset="18-32" id="DDI-PubMed.28806472.s17.e0" text="clarithromycin" /><entity charOffset="69-79" id="DDI-PubMed.28806472.s17.e1" text="evogliptin" /><pair ddi="false" e1="DDI-PubMed.28806472.s17.e0" e2="DDI-PubMed.28806472.s17.e0" /><pair ddi="false" e1="DDI-PubMed.28806472.s17.e0" e2="DDI-PubMed.28806472.s17.e1" /></sentence><sentence text="" /></document>